Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Inclusion Criteria: * be ≥ 18 years of age with documented pathological diagnosis of H\&N (head and neck) cancer. * planned to receive H\&N region IMRT treatment in which the mean dose to the dermis in the scalp risk zone (isodose plan) is estimated to be at least 20 Gy. * have a palpable nuchal prominence (external occipital protuberance) * have the ability to understand the informed consent document. * be able to comply with protocol schedule. * have a negative serum pregnancy test if a female of childbearing potential. * consent to utilize medically acceptable methods of contraception throughout the study if of childbearing potential. * be treated with IMRT alone or with concurrent platinum based chemotherapy * receive definitive treatment for oropharyngeal squamous cell carcinoma Exclusion Criteria: * with clinical or radiographic evidence of adenopathy to the high level V posterior cervical nodes, post-auricular or occipital cervical nodal stations * planned to receive H\&N region treatment in which the mean dose to the dermis in the scalp risk zone (isodose plan) is estimated to exceed 50Gy * with underlying active untreated cardiac disease (e.g. arrhythmia) * receiving concurrent chemotherapy other than single agent platinum based * with generalized skin disorders that have required treatment within the past 6 months. * with connective tissue disorders * with unhealed wounds or scars in the study area * with rashes, ulcerations, or poorly healed scars in the treatment area * with a known allergy to norepinephrine * with a known clinically significant abnormal ECG (electrocardiogram) within the past 6 months. * taking MAO (monoamine oxidase) inhibitors or antidepressants of the triptyline or imipramine types * taking β-blockers * with NCI-CTCAE Version 4.0 grade 2 or higher hypertension at the time of study entry.